Notice for selpercatinib (Eli Lilly Australia Pty Ltd)
Active ingredients
selpercatinib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Immediate release capsule
Indication
For the treatment of medullary thyroid cancer
Therapeutic area
Oncology